CNCE Stock Overview
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Concert Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.70|
|52 Week High||US$7.37|
|52 Week Low||US$2.57|
|1 Month Change||-1.18%|
|3 Month Change||56.91%|
|1 Year Change||108.08%|
|3 Year Change||14.33%|
|5 Year Change||-56.24%|
|Change since IPO||-52.75%|
Recent News & Updates
CinCor Pharma hits 52-week high on data for antihypertensive agent
News of a successful Phase 2 trial for CinCor Pharma’s (NASDAQ:CNCE) lead asset baxdrostat sent the company shares ~50% higher on Monday towards a 52-week high as Oppenheimer cheered the experimental drug for treatment-resistant hypertension. The BrigHtn trial involving 275 patients reached the primary endpoint and achieved a statistically significant placebo-adjusted reduction in systolic blood pressure, including 11 mmHg at a dose of 2 mg, CinCor (CNCE) said in a pre-market announcement. “We believe the totality of data exceeds our best-case scenario, and the level of placebo-adjusted SBP reduction beats the high-single-digit expectations,” Oppenheimer analysts led by Jay Olson wrote, noting the feedback from KOLs. As the company targets more aggressive goals to treat hypertension, “we believe baxdrostat holds the promise to change the treatment paradigm in” treatment-resistant hypertension, the analysts concluded, raising the price target for CinCor (CNCE) to $60 from $35 per share. Read: In March, the micro-cap stock joined the Russell 2000 and Russell 3000 Indexes.
|CNCE||US Biotechs||US Market|
Return vs Industry: CNCE exceeded the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: CNCE exceeded the US Market which returned -23.2% over the past year.
|CNCE Average Weekly Movement||8.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CNCE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CNCE's weekly volatility (9%) has been stable over the past year.
About the Company
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company’s lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals.
Concert Pharmaceuticals Fundamentals Summary
|CNCE fundamental statistics|
Is CNCE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNCE income statement (TTM)|
|Cost of Revenue||US$100.22m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.60|
|Net Profit Margin||-382.41%|
How did CNCE perform over the long term?See historical performance and comparison
Is CNCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNCE?
Other financial metrics that can be useful for relative valuation.
|What is CNCE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CNCE's PS Ratio compare to its peers?
|CNCE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ALPN Alpine Immune Sciences
SLNC.F Silence Therapeutics
SELB Selecta Biosciences
EIGR Eiger BioPharmaceuticals
CNCE Concert Pharmaceuticals
Price-To-Sales vs Peers: CNCE is good value based on its Price-To-Sales Ratio (9.9x) compared to the peer average (13.3x).
Price to Earnings Ratio vs Industry
How does CNCE's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CNCE is good value based on its Price-To-Sales Ratio (9.9x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is CNCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||9.9x|
|Fair PS Ratio||1.2x|
Price-To-Sales vs Fair Ratio: CNCE is expensive based on its Price-To-Sales Ratio (9.9x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Share Price vs Fair Value
What is the Fair Price of CNCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CNCE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CNCE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Concert Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNCE's revenue (61.7% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: CNCE's revenue (61.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Concert Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNCE is currently unprofitable.
Growing Profit Margin: CNCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.
Accelerating Growth: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: CNCE has a negative Return on Equity (-97.1%), as it is currently unprofitable.
Discover strong past performing companies
How is Concert Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CNCE's short term assets ($162.1M) exceed its short term liabilities ($16.2M).
Long Term Liabilities: CNCE's short term assets ($162.1M) exceed its long term liabilities ($32.4M).
Debt to Equity History and Analysis
Debt Level: CNCE is debt free.
Reducing Debt: CNCE has no debt compared to 5 years ago when its debt to equity ratio was 43.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNCE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CNCE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 25.7% each year.
Discover healthy companies
What is Concert Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Concert Pharmaceuticals Dividend Yield vs Market|
|Company (Concert Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Concert Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate CNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNCE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CNCE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Tung (62 yo)
Dr. Roger D. Tung, Ph D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...
CEO Compensation Analysis
|Roger Tung's Compensation vs Concert Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$4m||US$599k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$3m||US$582k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$3m||US$562k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$5m||US$536k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$3m||US$517k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$3m||US$500k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$711k||US$436k|
Compensation vs Market: Roger's total compensation ($USD3.53M) is about average for companies of similar size in the US market ($USD2.94M).
Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.
Experienced Management: CNCE's management team is considered experienced (4.7 years average tenure).
Experienced Board: CNCE's board of directors are seasoned and experienced ( 15.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|06 Jun 22||BuyUS$999,999||Richard Aldrich||Individual||210,526||US$4.75|
|06 Jun 22||BuyUS$49,999||Christine van Heek||Individual||10,526||US$4.75|
|06 Jun 22||BuyUS$28,500||Thomas Auchincloss||Individual||6,000||US$4.75|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Concert Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Concert Pharmaceuticals, Inc.
- Ticker: CNCE
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$321.162m
- Shares outstanding: 47.93m
- Website: https://www.concertpharma.com
Number of Employees
- Concert Pharmaceuticals, Inc.
- 65 Hayden Avenue
- Suite 3000N
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CNCE||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Feb 2014|
|73C||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.